Medical devices, healthcare technology and the business of care
PMA approval · P250051

Juveena Hydrogel System

Rejoni, Inc. · Decision date Sep 28, 2026

MEDTECHLEDGER EXPLANATIONP250051

What did the FDA approve?

The FDA approved the Juveena Hydrogel System from Rejoni, Inc. on September 28, 2026. The approval covers use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.

The approval also includes the Rejoni Acorn Catheter, which is indicated to access the uterine cavity and deliver the Juveena Hydrogel solution into the uterine cavity. The device is classified as an absorbable adhesion barrier under product code MCN in obstetrics and gynecology. The database record does not include supplement type or supplement reason fields.

FDA approval order statement

Approval for Juveena Hydrogel System. The Juveena Hydrogel System is indicated for use in adult women to reduce the incidence and severity of intrauterine adhesion formation following hysteroscopic adhesiolysis for symptomatic moderate to severe intrauterine adhesions.The Rejoni Acorn Catheter is indicated to access the uterine cavity and deliver the Juveena Hydrogel solution into the uterine cavity.
Regulatory pathway
Original PMA
Clinical specialty
Obstetrics/Gynecology
Decision date
Sep 28, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250051
Regulatory pathway
Premarket approval application
Applicant
Rejoni, Inc.
Product code
MCN
Decision code
APPR
Decision date
Sep 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Barrier, absorbable, adhesion.

Applicant
Rejoni, Inc.
Product code
MCN
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250051 received

    Application receipt date recorded by FDA.

  2. P250051 · FDA decision

    APPR

  3. P250051/S001 · Related supplement

    Juveena Hydrogel System

Timeline entries are records held by MedtechLedger for P250051. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250051

Product / regulatory recordCompanyPathwayDecision dateSource
Rejoni, Inc.PMA supplementOct 28, 2026FDA

Explore the linked device profile

Other records with product code MCN

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementNov 5, 2026FDA
Womed LeafP240015/S003
Womed SasPMA supplementOct 25, 2026FDA
Womed SasPMA approvalSep 9, 2025FDA
ETHICON, Inc.PMA approvalSep 15, 1989FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Rejoni, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Second Floor, Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records